Focal Therapy for Prostate Cancer Using HIFU
Recruiting now · Not applicable
Conditions studied: Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
In brief
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men achieving trifecta status (no erectile dysfunction, leak-free pad-free continence, cancer control). However, these trials have involved small numbers of patients with men selected for good baseline function. A multi-centre prospective trial within a larger cohort of men that better represents the patient population with prostate cancer (external validity) is required.
Key facts
- Study ID
- NCT01194648
- Run by
- University College, London
- People needed
- 354
- Starts
- 2011-06-29
- Expected to finish
- 2029-06-01
- Last updated by the study team
- 2018-04-20
Who can join
Age: any, up to 90. Sex: male. Healthy volunteers: not accepted.
Where it is running
- University College London — London, England, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.